Neogenomics Inc (NEO) Stock Analysis and Metrics

Neogenomics

NASDAQ: NEO

$14.10 ▼ -0.01 (-0.04%)

At close: Jul 13, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.93 Bn

P/E-19.49

P/S2.59

Div. Yield0.00

ROIC (Qtr)0.00

Revenue Growth (1y) (Qtr)11.09

Add ratio to table…

About

NeoGenomics, Inc. provides oncology diagnostic testing and consultative services including technical laboratory services and professional interpretation of test results by licensed physicians and molecular experts specializing in pathology and oncology. The company operates a network of cancer‑focused testing laboratories in the United States and the United Kingdom, with CAP‑accredited and CLIA‑certified facilities in Fort Myers Florida; Aliso Viejo and Carlsbad California; Durham North Carolina; Ramsey New Jersey; Houston Texas; and an ISO‑certified, CAP‑accredited full‑service laboratory in Cambridge United Kingdom. NeoGenomics’ mission is to save lives by improving patient care and its vision is to become the world’s leader in cancer testing information and decision support.

NeoGenomics generates revenue through clinical cancer testing, interpretation and consultative services, molecular and NGS testing, MRD testing, comprehensive technical and professional services, third‑party clinical trials and research support, validation laboratory services, and oncology data solutions. Its test portfolio includes cytogenetics, fluorescence in‑situ hybridization, flow cytometry, immunohistochemistry and digital imaging, molecular residual disease testing using next‑generation sequencing and flow cytometry, broad molecular testing panels such as PanTracer and Neo Comprehensive, and morphologic analysis performed by pathologists. These services are sold to healthcare providers, research institutions and pharmaceutical sponsors who require oncology‑focused diagnostic and biomarker data.

The company operates through the following segment:

• Reportable Segment: This segment encompasses a full suite of oncology diagnostic testing and consultative services, including technical components such as cytogenetics, FISH, flow cytometry, IHC and molecular testing, as well as professional components where physicians and molecular experts interpret results and provide consultation. The segment also offers oncology data solutions, validation laboratory services, and support for third‑party clinical trials, serving community‑based pathology and oncology practices, hospital pathology labs, reference labs, academic centers and pharmaceutical companies across the United States and the United Kingdom.

NeoGenomics holds a competitive position in the oncology testing market alongside large national laboratories such as Quest Diagnostics, Laboratory Corporation of America and ARUP, as well as specialized competitors including Guardant Health, Natera, Exact Sciences, Caris Life Science, Tempus AI and Myriad Genetics. The company differentiates itself through superior testing technologies and instrumentation, robust laboratory information systems, rapid turnaround times, a comprehensive test menu that combines technical and professional components, and a national direct sales force trained in cancer genetic testing and consultative selling.

NeoGenomics serves a diverse customer base that includes community‑based pathology and oncology practices, hospital pathology laboratories, reference laboratories, academic medical centers and pharmaceutical companies seeking oncology diagnostic, biomarker and clinical trial support services.

Investment Thesis

▲ Bull case

NeoGenomics' transformation in the Q1 FY26 reveals a compelling growth trajectory underpinned by the successful commercialization of next-generation products that are redefining its market position. The full commercial launch of RaDaR ST in February addresses a $20 billion addressable market for minimal residual disease monitoring, which management characterizes as significantly underpenetrated and rapidly expanding, indicating substantial room for market share capture beyond current penetration levels. This is further amplified by the receipt of MolDX reimbursement coverage for PanTracer LBx and the launch of PanTracer Pro, which together create a comprehensive liquid biopsy suite that directly addresses unmet needs in the community oncology setting where tissue biopsies are often infeasible. The strong historical growth of PanTracer Tissue, coupled with the new liquid biopsy offering, positions NeoGenomics to capitalize on the accelerating shift toward blood-based diagnostics in cancer care, a structural shift driven by clinical guidelines and patient preference for less invasive testing. Management's emphasis on these products as key differentiators for long-term predictable revenue growth suggests that the market may be underestimating the near-term inflection point in diagnostic innovation adoption, particularly as these tools integrate seamlessly into existing workflows through ongoing EPIC and LIMS system enhancements that reduce turnaround time and improve reimbursement capture.
The company's strategic focus on expanding its diagnostic and therapeutic relevance through biomarker innovation and strategic partnerships is creating multiple, underappreciated avenues for revenue diversification and margin expansion that extend beyond core NGS growth. NeoGenomics is actively developing new biomarkers such as B7-H3, CD137, EZH2, and PRMT5 to support biopharma partners advancing next-generation therapies like ADCs, BiTES, and bispecifics, positioning itself as an essential partner in the drug development and companion diagnostic ecosystem. This effort is complemented by the low-sample-input AML MRD flow assay in development, which promises higher sensitivity and faster turnaround times than existing solutions, addressing a critical unmet need in hematologic oncology where sample limitations hinder accurate monitoring. Furthermore, the partnership with Ultima Genomics to leverage the UG 100 sequencing platform for whole-genome sequencing represents a forward-looking investment in cost-effective, high-throughput technology that could significantly reduce the cost per test over time while expanding the test menu. These initiatives are not merely incremental; they reflect a deliberate strategy to evolve from a diagnostic provider to a precision medicine solutions partner, creating stickiness with both community providers and pharmaceutical clients that could drive higher-value contracts and reduce reliance on volatile commodity testing. The market may be overlooking how these investments in biomarker discovery and platform partnerships are laying the foundation for future pricing power and differentiation in an increasingly competitive landscape.
NeoGenomics' financial resilience and operational improvements are creating a foundation for sustainable margin expansion that is not fully reflected in current guidance, particularly as the company leverages scale and operational efficiencies to counteract near-term headwinds. Despite the dilutive impact of Pathline on average unit price, the company demonstrated meaningful progress in core pricing power, with average revenue per clinical test increasing 8% to $495 and 9% excluding Pathline, indicating that underlying pricing initiatives and test mix improvements are gaining traction. This is supported by ongoing revenue cycle management (RCM) efforts, strategic reimbursement pursuits, and the shift toward higher-value NGS tests, which continue to drive revenue per test growth even as volume expands. Operationally, the company achieved a 2% year-over-year decrease in total operating expenses to $99 million in Q1 2026, driven by disciplined cost management and the early benefits of integrating Pathline, which is expected to yield synergies in the second half of 2026. The reduction in operating expenses, combined with a 10% increase in gross profit to $81 million, contributed to a 27% year-over-year increase in adjusted EBITDA to $9.0 million, showcasing operating leverage that is beginning to manifest despite ongoing investments in R&D and sales force expansion. With the company guiding to $55–$57 million in adjusted EBITDA for full-year 2026 — representing a 27–31% increase from 2025 — and noting expectations to generate positive free cash flow in 2026, the market may be underappreciating how the combination of scaling diagnostic volume, operational efficiencies from LIMS and automation initiatives, and the maturation of the expanded sales force will drive faster-than-expected margin expansion as the year progresses, particularly as Pathline integration matures and higher-margin products like RaDaR ST and PanTracer Pro scale.

NeoGenomics' transformation in the Q1 FY26 reveals a compelling growth trajectory underpinned by the successful commercialization of next-generation products that are redefining its market position. The full commercial launch of RaDaR ST in February addresses a $20 billion addressable market for minimal residual disease monitoring, which management characterizes as significantly underpenetrated and rapidly expanding, indicating substantial room for market share capture beyond current penetration levels. This is further amplified by the receipt of MolDX reimbursement coverage for PanTracer LBx and the launch of PanTracer Pro, which together create a comprehensive liquid biopsy suite that directly addresses unmet needs in the community oncology setting where tissue biopsies are often infeasible. The strong historical growth of PanTracer Tissue, coupled with the new liquid biopsy offering, positions NeoGenomics to capitalize on the accelerating shift toward blood-based diagnostics in cancer care, a structural shift driven by clinical guidelines and patient preference for less invasive testing. Management's emphasis on these products as key differentiators for long-term predictable revenue growth suggests that the market may be underestimating the near-term inflection point in diagnostic innovation adoption, particularly as these tools integrate seamlessly into existing workflows through ongoing EPIC and LIMS system enhancements that reduce turnaround time and improve reimbursement capture.
The company's strategic focus on expanding its diagnostic and therapeutic relevance through biomarker innovation and strategic partnerships is creating multiple, underappreciated avenues for revenue diversification and margin expansion that extend beyond core NGS growth. NeoGenomics is actively developing new biomarkers such as B7-H3, CD137, EZH2, and PRMT5 to support biopharma partners advancing next-generation therapies like ADCs, BiTES, and bispecifics, positioning itself as an essential partner in the drug development and companion diagnostic ecosystem. This effort is complemented by the low-sample-input AML MRD flow assay in development, which promises higher sensitivity and faster turnaround times than existing solutions, addressing a critical unmet need in hematologic oncology where sample limitations hinder accurate monitoring. Furthermore, the partnership with Ultima Genomics to leverage the UG 100 sequencing platform for whole-genome sequencing represents a forward-looking investment in cost-effective, high-throughput technology that could significantly reduce the cost per test over time while expanding the test menu. These initiatives are not merely incremental; they reflect a deliberate strategy to evolve from a diagnostic provider to a precision medicine solutions partner, creating stickiness with both community providers and pharmaceutical clients that could drive higher-value contracts and reduce reliance on volatile commodity testing. The market may be overlooking how these investments in biomarker discovery and platform partnerships are laying the foundation for future pricing power and differentiation in an increasingly competitive landscape.
NeoGenomics' financial resilience and operational improvements are creating a foundation for sustainable margin expansion that is not fully reflected in current guidance, particularly as the company leverages scale and operational efficiencies to counteract near-term headwinds. Despite the dilutive impact of Pathline on average unit price, the company demonstrated meaningful progress in core pricing power, with average revenue per clinical test increasing 8% to $495 and 9% excluding Pathline, indicating that underlying pricing initiatives and test mix improvements are gaining traction. This is supported by ongoing revenue cycle management (RCM) efforts, strategic reimbursement pursuits, and the shift toward higher-value NGS tests, which continue to drive revenue per test growth even as volume expands. Operationally, the company achieved a 2% year-over-year decrease in total operating expenses to $99 million in Q1 2026, driven by disciplined cost management and the early benefits of integrating Pathline, which is expected to yield synergies in the second half of 2026. The reduction in operating expenses, combined with a 10% increase in gross profit to $81 million, contributed to a 27% year-over-year increase in adjusted EBITDA to $9.0 million, showcasing operating leverage that is beginning to manifest despite ongoing investments in R&D and sales force expansion. With the company guiding to $55–$57 million in adjusted EBITDA for full-year 2026 — representing a 27–31% increase from 2025 — and noting expectations to generate positive free cash flow in 2026, the market may be underappreciating how the combination of scaling diagnostic volume, operational efficiencies from LIMS and automation initiatives, and the maturation of the expanded sales force will drive faster-than-expected margin expansion as the year progresses, particularly as Pathline integration matures and higher-margin products like RaDaR ST and PanTracer Pro scale.

▼ Bear case

NeoGenomics faces significant near-term headwinds in its non-clinical business that are being inadequately addressed in management's forward-looking statements, posing a material risk to overall revenue stability and growth consistency. The company explicitly acknowledged that pharma and biotech spending has not rebounded sufficiently, with recent tariff announcements, trade headwinds, and potential NIH funding cuts expected to reduce R&D spend across its non-clinical customer base, which represents approximately 10% of total revenue but remains a drag on growth. Furthermore, most pharma trials utilizing RaDaR 1.0 have concluded, and the company's inability to sell new RaDaR 1.0 contracts due to a negotiated settlement directly undermines a historical revenue stream. While management expresses confidence in the long-term strategic value of this business and points to future growth through new products and go-to-market improvements, the current trajectory shows a 15.8% year-over-year decline in non-clinical revenue in Q1 2026, and the guidance assumes this decline will persist throughout 2026, offset only by clinical growth. The market may be overlooking how prolonged weakness in this segment could strain resources, delay reinvestment into innovation, and create a persistent growth drag that requires more than incremental clinical gains to overcome, especially if biotech capital formation remains subdued due to macroeconomic uncertainty.
The integration and financial contribution of the Pathline acquisition are proving more dilutive and slower to accrue than management's optimistic projections suggest, creating a tangible risk to near-term margin expansion and earnings quality. Management acknowledged that Pathline is expected to lower adjusted gross margins and adjusted EBITDA for the remainder of 2025 as operations are optimized, with a negative adjusted EBITDA impact of $2 million in Q2 and a potential additional $1 million for the rest of the year. In Q1 2026, the dilutive effect was evident in the average revenue per test, where the inclusion of Pathline tests reduced the blended rate despite core NeoGenomics showing stronger pricing trends. Furthermore, the realization of benefits from integrating NeoGenomics' test menu into Pathline's operations — such as cross-selling the full NGS panel — is not expected to meaningfully contribute until Q4 2026 or Q1 2027, as significant validation work must first be completed. This delay in synergy capture means that the $12–$14 million in anticipated 2025 revenue from Pathline is coming with a sustained earnings drag, and the company's reliance on this acquisition to drive future growth may be overstated if integration challenges persist or if the acquired business fails to adopt the higher-margin NeoGenomics test menu at the anticipated pace. The market may be underestimating the operational complexity and time required to fully integrate Pathline, particularly given the differences in operational maturity and test menu breadth between the two entities, which could prolong the period during which Pathline remains a margin dilutive asset rather than an accretive one.
NeoGenomics' guidance and commentary suggest an overreliance on uncertain macroeconomic and reimbursement tailwinds that may not materialize as expected, creating a risk to the achievability of its financial targets and masking underlying growth challenges. The company cites ongoing state biomarker legislation as a long-term tailwind for improved pricing and cash collections, but acknowledges this is a slow-developing process with no near-term impact, yet still implies it will support future margin expansion without providing concrete timelines or measurable progress. Similarly, management expressed confidence that the potential cost impact of new tariffs would be manageable and offset by other savings initiatives, despite sourcing a majority of supplies from U.S.-based manufacturers, which leaves the company exposed to potential input cost inflation if tariffs escalate or supply chain disruptions occur. The reliance on these uncertain external factors — legislative progress and trade policy stability — to support financial goals introduces vulnerability, especially if reimbursement reforms stall or tariff pressures increase input costs faster than operational efficiencies can absorb them. Furthermore, the company's expectation of accelerating NGS growth in the back half of the year, predicated on easier comparisons and sales force maturation, may not hold if demand for diagnostic testing in the community setting does not strengthen as anticipated, leaving the company vulnerable to a scenario where both organic growth and integration benefits fall short of projections, thereby calling into question the validity of the current guidance range.

NeoGenomics faces significant near-term headwinds in its non-clinical business that are being inadequately addressed in management's forward-looking statements, posing a material risk to overall revenue stability and growth consistency. The company explicitly acknowledged that pharma and biotech spending has not rebounded sufficiently, with recent tariff announcements, trade headwinds, and potential NIH funding cuts expected to reduce R&D spend across its non-clinical customer base, which represents approximately 10% of total revenue but remains a drag on growth. Furthermore, most pharma trials utilizing RaDaR 1.0 have concluded, and the company's inability to sell new RaDaR 1.0 contracts due to a negotiated settlement directly undermines a historical revenue stream. While management expresses confidence in the long-term strategic value of this business and points to future growth through new products and go-to-market improvements, the current trajectory shows a 15.8% year-over-year decline in non-clinical revenue in Q1 2026, and the guidance assumes this decline will persist throughout 2026, offset only by clinical growth. The market may be overlooking how prolonged weakness in this segment could strain resources, delay reinvestment into innovation, and create a persistent growth drag that requires more than incremental clinical gains to overcome, especially if biotech capital formation remains subdued due to macroeconomic uncertainty.
The integration and financial contribution of the Pathline acquisition are proving more dilutive and slower to accrue than management's optimistic projections suggest, creating a tangible risk to near-term margin expansion and earnings quality. Management acknowledged that Pathline is expected to lower adjusted gross margins and adjusted EBITDA for the remainder of 2025 as operations are optimized, with a negative adjusted EBITDA impact of $2 million in Q2 and a potential additional $1 million for the rest of the year. In Q1 2026, the dilutive effect was evident in the average revenue per test, where the inclusion of Pathline tests reduced the blended rate despite core NeoGenomics showing stronger pricing trends. Furthermore, the realization of benefits from integrating NeoGenomics' test menu into Pathline's operations — such as cross-selling the full NGS panel — is not expected to meaningfully contribute until Q4 2026 or Q1 2027, as significant validation work must first be completed. This delay in synergy capture means that the $12–$14 million in anticipated 2025 revenue from Pathline is coming with a sustained earnings drag, and the company's reliance on this acquisition to drive future growth may be overstated if integration challenges persist or if the acquired business fails to adopt the higher-margin NeoGenomics test menu at the anticipated pace. The market may be underestimating the operational complexity and time required to fully integrate Pathline, particularly given the differences in operational maturity and test menu breadth between the two entities, which could prolong the period during which Pathline remains a margin dilutive asset rather than an accretive one.
NeoGenomics' guidance and commentary suggest an overreliance on uncertain macroeconomic and reimbursement tailwinds that may not materialize as expected, creating a risk to the achievability of its financial targets and masking underlying growth challenges. The company cites ongoing state biomarker legislation as a long-term tailwind for improved pricing and cash collections, but acknowledges this is a slow-developing process with no near-term impact, yet still implies it will support future margin expansion without providing concrete timelines or measurable progress. Similarly, management expressed confidence that the potential cost impact of new tariffs would be manageable and offset by other savings initiatives, despite sourcing a majority of supplies from U.S.-based manufacturers, which leaves the company exposed to potential input cost inflation if tariffs escalate or supply chain disruptions occur. The reliance on these uncertain external factors — legislative progress and trade policy stability — to support financial goals introduces vulnerability, especially if reimbursement reforms stall or tariff pressures increase input costs faster than operational efficiencies can absorb them. Furthermore, the company's expectation of accelerating NGS growth in the back half of the year, predicated on easier comparisons and sales force maturation, may not hold if demand for diagnostic testing in the community setting does not strengthen as anticipated, leaving the company vulnerable to a scenario where both organic growth and integration benefits fall short of projections, thereby calling into question the validity of the current guidance range.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Diagnostics & Research

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	WAT	Waters Corp /De/	31,055.11 Bn	69,126.88	8,236.16	4.86 Bn
2	TMO	Thermo Fisher Scientific Inc.	191.02 Bn	27.63	4.23	43.16 Bn
3	DHR	Danaher Corp /De/	137.16 Bn	37.32	5.54	18.48 Bn
4	IDXX	Idexx Laboratories Inc /De	42.82 Bn	39.09	9.63	0.83 Bn
5	NTRA	Natera, Inc.	39.09 Bn	-172.71	15.63	0.02 Bn
6	A	Agilent Technologies, Inc.	37.61 Bn	26.60	5.20	0.30 Bn
7	IQV	Iqvia Holdings Inc.	34.23 Bn	35.84	2.06	15.83 Bn
8	ILMN	Illumina, Inc.	28.14 Bn	32.98	6.40	1.49 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password